Nonclinical development of biopharmaceuticals
- 1 December 2009
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 14 (23-24) , 1112-1122
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Nonclinical Aspects of Biopharmaceutical Development: Discussion of Case Studies at a PhRMA-FDA WorkshopInternational Journal of Toxicology, 2008
- Preclinical development of therapeutic biologicsExpert Opinion on Drug Discovery, 2008
- Development trends for monoclonal antibody cancer therapeuticsNature Reviews Drug Discovery, 2007
- Emerging monoclonal antibody therapies for malignant gliomasExpert Opinion on Investigational Drugs, 2007
- Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived PharmaceuticalsBioDrugs, 2006
- Early Development of Therapeutic Biologics - PharmacokineticsCurrent Drug Metabolism, 2006
- Biopharmaceuticals: recent approvals and likely directionsTrends in Biotechnology, 2005
- Monoclonal antibody successes in the clinicNature Biotechnology, 2005
- Recombinant protein therapeutics—success rates, market trends and values to 2010Nature Biotechnology, 2004
- Nonclinical safety evaluation of biotechnologically derived pharmaceuticals2000